Idorsia Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	7.4yrs
Gemiddelde ambtstermijn bestuur	3.5yrs

Recente managementupdates

Recent updates

CEO

Idorsia heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Andre Muller	Executive VP & CFO	7.8yrs	geen gegevens	0.056% $ 90.7k
Martine Clozel	Executive VP & Chief Scientific Officer	7.8yrs	geen gegevens	6.79% $ 11.1m
Guy Braunstein	Executive VP & Chief Medical Officer	no data	geen gegevens	0.11% $ 176.5k
Alberto Gimona	Executive VP & Head of Global Clinical Development	5.8yrs	geen gegevens	0.0071% $ 11.5k
Andrew Weiss	Senior VP and Head of Investor Relations & Corporate Communications	7.4yrs	geen gegevens	geen gegevens
Julien Gander	Senior VP	2yrs	geen gegevens	geen gegevens
Alexander Khatuntsev	Senior VP & Head of Global Human Resources	7.4yrs	geen gegevens	geen gegevens
Olivier Lambert	Senior VP & Head of Technical Operations	no data	geen gegevens	geen gegevens
Markus Riederer	Senior VP & Head of Drug Discovery Biology	no data	geen gegevens	geen gegevens
Christoph Boss	Senior VP & Head of Drug Discovery Chemistry	no data	geen gegevens	geen gegevens

7.4yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IDRS.F is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Kellogg	Non-Executive Director	3.5yrs	CHF 149.37k	0.020% $ 33.0k
Jean-Paul Clozel	Chairman of the Board	less than a year	CHF 1.98m	19.04% $ 31.0m
Joern Aldag	Non-Executive Director	4.5yrs	CHF 156.82k	0.021% $ 34.4k
Felix Ehrat	Non-Executive Director	4.5yrs	CHF 174.78k	0.054% $ 88.0k
Bart Filius	Non-Executive Director	less than a year	geen gegevens	geen gegevens
Mathieu Simon	Vice-Chairman & Lead Independent Director	5.5yrs	CHF 344.19k	0.069% $ 112.2k
Sophie Kornowski-Bonnet	Non-Executive Director	1.5yrs	CHF 117.54k	0.012% $ 19.8k
Sandesh Mahatme	Non-Executive Director	4.5yrs	CHF 172.30k	0.025% $ 40.7k
Srishti Gupta	Non-Executive Director	3.5yrs	CHF 161.88k	0.025% $ 40.1k

3.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IDRS.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Idorsia Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Idorsia Ltd Approves Board Appointments

Recent updates

Idorsia's Once-Daily Tryvio (Aprocitentan) Is Now Available in the U.S., Advancing Treatment Options for Millions of Patients with Difficult-To-Control Hypertension

Idorsia Ltd Provides Earnings Guidance for 2024

Idorsia Ltd to Report Fiscal Year 2024 Results on Feb 27, 2025

Idorsia Ltd Receives Approval from the European Commission for JERAYGO™

Idorsia Ltd Approves Board Appointments

Idorsia Ltd to Report Nine Months, 2024 Results on Oct 29, 2024

Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023

Idorsia Ltd Updates Earnings Guidance for the Year 2023

Idorsia Ltd to Report Q1, 2024 Results on Apr 25, 2024

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Idorsia Ltd to Report Q3, 2023 Results on Oct 24, 2023

Idorsia Ltd Submits New Drug Application to the US FDA for Aprocitentan for Treatment of Patients with Difficult-to-Control Hypertension

Idorsia Ltd Announces Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs

Idorsia Ltd Announces Swissmedic Approves QUVIVIQ (daridorexant) – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

Idorsia Ltd Provides Earnings Guidance for the Year 2022

Idorsia Ltd to Report Q1, 2023 Results on Apr 25, 2023

Idorsia Ltd Announces Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension

Idorsia Ltd Announces Phase 2A Study Results in Binge Eating Disorder

Idorsia Ltd to Report Fiscal Year 2022 Results on Feb 07, 2023

Idorsia Ltd and Idorsia Pharmaceuticals Japan Announces Availability of Pivlaz™ (Clazosentan) to Physicians in Japan to Start Treating Asah Patients

Idorsia Ltd Announces Revenue Guidance for Full Year 2022

Idorsia Receives US FDA Approval of QUVIVIQ (daridorexant) 25 and 50 mg for the Treatment of Adults with Insomnia

Idorsia to Present New Phase 3 Data on Daridorexant in Insomnia at Sleep 2021

Idorsia Ltd Announces US FDA Approves Ponvory (ponesimod) to Treat Adults with Relapsing Forms of Multiple Sclerosis

FDA Accepts the New Drug Application for Review of Idorsia’s Daridorexant for the Treatment of Adult Patients with Insomnia

Idorsia Ltd Announces Submission of New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Clazosenta

Idorsia Ltd to Report Q3, 2021 Results on Oct 26, 2021

Idorsia Ltd to Report First Half, 2021 Results on Jul 27, 2021

Idorsia Ltd to Report Q1, 2021 Results on Apr 22, 2021

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd